Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Who we help

As the trusted partner to the top 50 global pharmaceutical companies and top 10 contract research organizations, our pharmaceutical data, insights, and analytics are used by businesses operating in all areas of the industry.

Our Specialties

For pharmaceutical companies

Bring game-changing drugs to market more efficiently using our insight and analysis. We’ll help you beat the competition and improve healthcare and patient outcomes.

For contract research organizations

We can help position your organization to win more business and enhance your drug development services. You’ll make better-informed, data-driven decisions while bidding on and implementing clinical trials.

For consultancies

Focus on your clients and expand your business opportunities with Pharma Intelligence. We’ll help you build a complete picture of the fast-changing pharmaceutical market with our insight and expertise.

For marketing agencies

You need to understand and communicate complex information simply and persuasively, often across a variety of channels. We can help with branding, multi-channel communication and more.

For the medtech sector

Your trusted source for industry data, analysis, opinion and news. Access the information you need to inform deal making and business cases for product development and quality control and compliance.

For financial services companies

We help you successfully execute on your biopharma strategy with real-time data and solutions supported by our in-house team of analysts.

Relevant products

Trialtrove: gold standard clinical trials intelligence

Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.

Key benefits:

Curated by experts
Clinical trial landscape view
Ask-the-Analyst™

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Thought leadership, Pharma Marketing Solutions

Putting Account-Based Marketing to work for your high-value clients

13 Sep 2021

Account-based marketing/engagement (ABM/ABE): this customer-centric, cross-functional approach to delivering clients and prospective clients superior marketing campaigns has become increasingly popular.

Topic Market Intelligence

Single report
Biomedtracker, Meddevicetracker

Q3 2021 Outlook Report

27 Aug 2021

What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.

Topic Drug Review

Single report
Medtech Insight

More Problems For Software Used In Baxter Spectrum IQ Infusion Pumps

By Shawn M. Schmitt 26 Aug 2021

Baxter says customers complained of “multiple pumps within their fleets” encountering system errors after they made changes to their network configuration and server systems. It’s the second software-related setback for the device maker in recent weeks.

View article
Pharma Consulting

ASGCT/Pharma Intelligence Quarterly Report: Q2 2021

20 Aug 2021

We’re excited to share our latest Q2 report on Gene, Cell, & RNA Therapies with The American Society of Gene & Cell Therapy (ASGCT). This newest report calls out some important updates and changes within the Gene, Cell, & RNA Therapy Landscape.

Topic Cell & Gene Therapy

Single report
Medtech Insight

2 Deaths Linked To Missing IFU For Cardinal Health Scalpel Used For Newborns

By Shawn M. Schmitt 20 Aug 2021

The Safety Scalpel N11 is a component of Cardinal Health’s Argyle UVC Insertion Tray, which was recalled because it didn’t include the scalpel’s instructions for use. The recall has been labeled high-risk class I by the US FDA.

View article
Generics Bulletin

India Biosimilars Landscape

19 Aug 2021

India leads the ways with the highest number of approved biosimilars.

Topic Clinical Trials Biosimilars

View infographic
In Vivo

Critical Insights into Market Access

18 Aug 2021

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

View infographic
Scrip

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

By Dexter Yan 18 Aug 2021

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

View article
Pharma Marketing Solutions, Lead generation, Pharma Brand Aw...

Benefit from the trust our subscribers have in us and reach your target audience

17 Aug 2021

As the world’s leading provider of news, analysis, and data for the pharmaceutical, generics, consumer healthcare, and medtech markets, we know your target audience – they’re our subscribers.

Topic Market Intelligence

View infographic
HBW Insight

US FDA Focused On Vulnerable Populations As Cosmetic Risk Assessment Protocol Develops

By Ryan Nelson 17 Aug 2021

The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.

View article
In Vivo

‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

By William Masters 16 Aug 2021

Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

View article
Pink Sheet

AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

By Sue Sutter 16 Aug 2021

After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 16 Aug 2021

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

View article
Pharmaprojects, Citeline

Pharma R&D Annual Review & NAS Supplement 2021

By Ian Lloyd 13 Aug 2021

Our world was disrupted at warp speed during 2020. Are you ready to gain a deeper understanding of the year that changed our perceptions of possible?

Topic Clinical Trials Diseases Drug Review

View white paper
HBW Insight

After US FDA Objects To CBD Safety As NDIs, Supplement Industry Responds, What Else Is New?

By Malcolm Spicer 13 Aug 2021

Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.

View article